Background: To date, common genetic variants in approximately 70 loci have been identified for breast cancer via genome-wide association studies (GWAS). It is unknown whether rare variants in these loci are also associated with breast cancer risk.
Introduction
Breast cancer is one of the most commonly diagnosed malignancies of women in the world (1) . It is well established that genetic factors play an important role in breast cancer risk (2) . Over the past several years, common variants, usually with minor allele frequency (MAF) > 5%, in approximately 70 loci have been identified as breast cancer risk factors via genome-wide association studies (GWAS; ref. 3) . However, these common variants together explained only a small portion of the heritability for breast cancer.
It has been increasingly recognized that the missing heritability for breast cancer and other complex diseases may be partially explained by low-frequency variants. There are a large number of low-frequency variants in the human genome, and these rare coding variants are enriched for functional importance (4) . Rare coding variants have been associated with multiple diseases, such as the MTNR1B gene for type 2 diabetes (5), IFIH1 gene for type 1 diabetes (6), APOA5, GCKR, LPL, and APOB genes for hypertriglyceridemia (7) and CHEK2, ATM, BRIP1, PALB2, RAD51C, RAD51D, and PPM1D genes for breast cancer (8) (9) (10) (11) (12) (13) . Herein, we investigated low MAF coding variants in GWAS-identified loci regions for their association with breast cancer risk. Focusing on the flanking 500-kb regions of 67 GWAS-identified loci, we investigated low MAF nonsense/missense variants and their corresponding genes in a total of 3,472 cases and 3,595 controls from the Shanghai Breast Cancer Genetics Study.
Materials and Methods

Study populations
Study participants in the present study were drawn from four population-based studies conducted in Shanghai, the Shanghai Breast Cancer Study (SBCS), Shanghai Women's Health Study (SWHS), Shanghai Breast Cancer Survival Study (SBCSS), and the Shanghai Endometrial Cancer Study (SECS, contributed control data only). Detailed descriptions of participating studies have been published elsewhere (14) (15) (16) . In brief, the SBCS is a twostage (SBCS-I and SBCS-II), population-based, case-control study. SBCS-I recruitment occurred between August 1996 and March 1998; SBCS-II recruitment occurred between April 2002 and February 2005. Both studies identified patients with incident primary breast cancer through the population-based Shanghai Cancer Registry and randomly selected community controls from the general population in Shanghai. The SBCSS included newly diagnosed breast cancer cases ascertained via the Shanghai Cancer Registry between April 2002 and December 2006. The SECS is a population-based, casecontrol study of endometrial cancer conducted between January 1997 and December 2003 using a protocol similar to the SBCS; only community controls from the SECS were included in the present study. The SWHS is a populationbased prospective cohort study of women from urban communities in Shanghai who were recruited between 1996 and 2000. The cohort has been followed by a combination of record linkage and active follow-ups to identify cause-specific mortality and cancer incidence by sites. All these studies are conducted among Chinese women in Shanghai, a genetically homogenous population, using very similar protocols in data and sample collection. Genomic DNA for all included participants was extracted using commercial DNA purification kits. Study protocols were approved by the institutional review boards of all institutions involved in the study, and informed consents were obtained from all study participants.
Genotyping array
Genotype assays were done by the Asian Exomechip, an expanded Illumina HumanExome-12v1_A Beadchip. The original exome array includes 247,870 markers focused on protein-coding regions selected from >12,000 samples with exome and genome sequencing data. The vast majority of these samples were from European ancestry populations, and approximately 600 Asian samples were included. Details about single-nucleotide polymorphism (SNP) contents and characteristics are described at Exomechip design (17). In brief, nonsynonymous variants observed three or more times in at least two studies, and splicing and stopaltering variants observed two or more times in at least two studies were selected. Additional array content includes variants associated with complex traits in previous GWAS, human leukocyte antigen tags, ancestryinformative markers, markers for identity-by-descent estimation, and random synonymous SNPs.
To improve the coverage for the low frequency variants in Asian population, we designed the Asian Exomechip by adding approximately 60K customer content variants onto the Illumina HumanExome-12v1_A Beadchip based on additional sequencing data. Included on the chip are also top SNPs selected from GWAS for follow-up. Three sequencing datasets were used to add additional nonsense/missense variants: exome sequencing in 581 Chinese women from SBCS, exome sequencing in 496 Singapore Chinese, and Asian data in the 1000 Genomes Project. Nonsynonymous, splicing, and stop-altering variants observed two or more times in any of these datasets or once in any two of the three datasets, were added (N ¼ 33,342). Additional common variants (N ¼ 28,637) were added to the chip for various GWAS follow-up and GWAS loci fine-mapping projects.
Genotyping and quality control
All samples were genotyped at the Genome Quebec Innovation Centre (Montreal, Quebec, Canada) following Illumina's protocol. On each 96-well plate, blind duplicate samples and two HapMap samples were included as quality control (QC). Genotype calling was carried out using Illumina's GenTrain version 2.0 clustering algorithm in GenomeStudio version 2011.1. Cluster boundaries were determined using study samples. After clustering, approximately 80,000 variants were manually reviewed and clusters were edited for 27,506 variants.
Further QC procedures were conducted using plink (18) . We evaluated concordance rates for HapMap samples genotyped in our study and sequenced by the 1,000 Genomes Project (4). Principal components analyses (PCA) were conducted based on 3,200 ancestry informative markers on the Exomechip using EIGENSTRAT (19) to identify population outliers with the 1,000 Genomes Project data as reference. We also estimated pair-wise proportion of identify-by-descent to identify potentially genetically identical, unexpected duplicated samples or close relatives. The samples were excluded if (i) call rate < 98%, or (ii) consistence rates between the HapMap samples with 1000 Genomes data <99%, or (iii) heterozygosity outlier, or (iv) ethnic outliers, or (v) samples with close relationship, or (vi) consistence rates among duplicated samples < 99%, or (vii) samples with wrong sex. The SNPs were excluded if (i) MAF ¼ 0, or (ii) call rate <98%, or (iii) genotyping concordance rate <98% in QC samples, or (iv) Hardy-Weinberg equilibrium test P < 10 
Statistical Analyses
We used ANNOVAR program (20) to annotate all SNPs. We included all missense/nonsense variants located flanking 500 kb of the indexed SNP of 67 GWAS loci. If a protein-coding gene was partially covered within the flanking 500-kb region, all missense/nonsense variants in the whole gene were included for analyses. For singlevariant analysis, we used logistic score test adjusted for age implemented in Efficient and Parallelizable Association Container Toolbox (EPACTS) package (21) . Further conditional analyses were conducted by adjusting the corresponding index SNP in each locus.
For gene-based analysis, we used the SKAT-O test with default parameters implemented in the EPACTS package. SKAT-O (22) encompasses burden tests and SKAT (23) . Low-frequency variants of MAF 5% or MAF 1% within each gene were aggregated.
Results
Characteristics of the study population are shown in Table 1 . All the known risk factors were associated with breast cancer risk in this study setting. Cases had higher educational attainment and were more likely to have a first-degree relative with breast cancer, a history of benign breast disease, be postmenopausal, and report early menarche than controls.
Single marker analyses
In the flanking regions of those 67 GWAS loci, a total of 1,272 missense/nonsense variants were included on the chip; 1,080 were rare variants with 0 < MAF 5% (Supplementary Table S1 ). A total of 38 rare variants (0 < MAF 5%) showed an association with breast cancer risk at P < 0.05 after adjusted for the corresponding index SNP (Table  2) . Notably, five rare variants were associated with breast cancer risk at P < 0.01. SNP rs146217902 in the EDEM1 at 3p26.1 and rs200340088 in the EFEMP2 at 11q13.1 were observed in 8 cases but not in any controls (P ¼ 0.004 for both). Another SNP rs200995432 in the EFEMP2 gene was associated with increased breast cancer risk with an OR of 6.2 [95% confidence interval (CI), 1.4-27.6; P ¼ 6.2 Â 10 À3 ]. SNP rs80358978 in the BRCA2 gene, 42 kb upstream from the GWAS SNP rs11571833, was associated with 16.5-fold elevated risk (95% CI, 2.2-124.5; P ¼ 2.2 Â 10 À4 ). A rare variant rs143563006 in the FBXO18 gene was associated with decreased risk of breast cancer with an OR being 0.60 (95% CI, 0.41-0.88) and a P value of 8.2 Â 10 À3 .
Gene-based analyses
Collapsing variants with MAF 5% within each gene suggested eight genes associated with breast cancer at P < 0.05 (Table 3 and Supplementary Table S2 ). As the MAF of the majority of rare variants was 1%, similar results were found when MAF was set to 1%. These associations did not change materially after adjusting for corresponding GWAS index SNPs. At the locus 11q13.1, two genes, EFEMP2 and RNASEH2C, showed an association with breast cancer risk with P ¼ 0.002 and P ¼ 0.04, respectively. The EFEMP2 gene was approximately 61.3 kb downstream from the GWAS SNP rs12575663, and the RNASEH2C gene was 87 kb upstream from the index SNP. At the 10p15.1, the FBXO18 (consisting of 5 variants with MAF < 0.05) was strongly associated with breast cancer risk (P ¼ 8.0 Â 10
À3
). The other five genes showing associations were KLHL26, OR2A12, TGFBR2, TRIP13, and VTI1A.
Discussion
In the present study, we investigated associations of 1,080 missense/nonsense variants with an MAF of 5% in 337 genes at 67 GWAS loci among 3,472 Chinese breast cancer cases and 3,595 controls. Single marker analyses showed an association for 38 variants at P < 0.05. In particular, five variants were associated with breast cancer risk at P < 0.01, including rs200340088 and rs200995432 in EFEMP2, rs146217902 in EDEM1, rs143563006 in FBXO18, and rs80358978 in BRCA2. Gene-based analyses showed an association at P < 0.01 for EFEMP2 and FBXO18 genes and at P < 0.05 for six genes, including RNASEH2C, KLHL26, OR2A12, TGFBR2, TRIP13, and VTI1A. The most significant association was observed for a missense variant, rs80358978 (Gly2508Ser), in the BRCA2 gene. It was 42 kb upstream from the GWAS SNP rs11571833. This variant was observed in 16 heterozygous breast cancer cases and only one control participant. This variant was not present among the 1,092 individuals included in the 1,000 Genomes Project or the 6,400 individuals of European or African ancestry included in the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (24) . This variant was found in four Asian breast cancer women in the Breast Cancer Information Core (25) . Though the clinical importance of this variant was unknown, it may be potentially functional and it is predicted to be "probably damaging" based on its Polyphen-2 score (0.999) and "deleterious" based on its sorting intolerant from tolerant (SIFT) score (0).
In addition, of the 38 rare variants causing missense mutations, the predominantly single amino acid change is from a basic or acidic amino acid to a neutral amino acid, such is the case for CCDC88C, MAP3K1, and SRRM5 genes are predicted to be deleterious based on the SIFT score ( Table 2) . It further suggests, to some extent, that these rare missense mutations would affect the protein's topologic structure and physicochemical properties.
For gene-based analysis, our results indicated that the significant association with breast cancer risk is driven by one single variant in each gene. The reason is greatly related to our focuses on the missense/nonsense variants with low frequency. Generally speaking, the consequence of missense mutations has direct impacts on protein structure and function. Thus, it is more likely to undergo purifying selection (26, 27) , making the probability of two or more rare missense mutations happening in the same gene quite low.
The most significant result from gene-based analyses is for the association observed with the EFEMP2 gene, encoding a protein containing four EGF2 domains and six calcium-binding EGF2 domains. This gene is necessary for elastic fiber formation and connective tissue development (28) . Several studies indicated that the expression level of the EFEMP2 gene, even at an early cancer stage, was increased in cancer tissues of the patients with colorectal and endometrial cancer (29) (30) (31) . RNASEH2C, another gene located at the 11q13.1 locus, also showed a significant association in this study. This gene encodes one of Ribonuclease H2 (RNase H2) subunits, a major nuclear enzyme involved in the degradation of RNA/DNA hybrids and removal of ribonucleotides misincorporated in genomic DNA to maintain genomic integrity. Mutations in each of the three RNase H2 genes have been implicated in a human autoinflammatory disorder, Aicardi-Gouti eres syndrome (32, 33) . Crystal structure of the RNase H2 complex indicated that residues in the Cterminal kinked helix (RNASEH2C:143-160) contact both RNASEH2A and RNASEH2B (34) , suggesting the detected variant (R145L) in the RNASEH2C gene may influence the complex formation of RNase H2.
FBXO18 (also called FBH1 or FBX18) is a member of the UvrD family of DNA helicases (35, 36) . Its helicase activity induces DNA double-strand breakage and activation of ATM and DNA-PK and phosphorylation of RPA2 and p53 (37) . The ATM and p53 genes are two of the most wellestablished breast cancer susceptibility genes. A previous study has revealed a connection between rare missense variants in the ATM gene and breast cancer risk (11) . Here, we provide evidence that rare variants in the FBXO18 gene may also contribute to the risk of breast cancer. It has been well established that the TGF-b pathway plays a critical role in the development and progression of a large number of human cancers, including breast cancer (38) (39) (40) . TGF-b1 is the most abundant form of TGF-b and regulates cellular processes by binding to TGFBR2. Therefore, defective expression of TGFBR2 may play a significant role in carcinogenesis. Our previous evaluation of the associations of genetic variants in the TGF-b signaling pathway with breast cancer risk found that one common SNP (rs1078985) in the TGFBR2 was associated with breast cancer risk (41) . The gene-based results in this study provide further evidence that the TGFBR2 gene is significantly associated with breast cancer risk.
In the present study, we identified multiple rare coding variants associated with breast cancer in GWA-identified loci. However, after adjusting for multiple comparisons, some of them became insignificant. The statistical power in the present study is limited for rare variants, even though more than 6,000 cases and controls were included. Independent studies with larger sample size are warranted to clarify the relationship between this rare variants and breast cancer risk.
In conclusion, we identified associations of additional genes/variants flanking the known susceptibility loci with breast cancer risk. These findings may provide new insights into the etiology of breast cancer as well as future potential therapeutic targets.
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